N. M. Keith, H. P. Wagener, and J. W. Kernohan, The syndrome of malignant hypertension, Arch Intern Med, vol.41, issue.2, pp.141-88, 1928.

P. Kimmelstiel and C. Wilson, Benign and Malignant Hypertension and Nephrosclerosis: A Clinical and Pathological Study, Arch Intern Med, vol.34, issue.3, pp.374-87, 1924.

N. M. Keith, H. P. Wagener, and N. W. Barker, Some different types of essential hypertension: their course and prognosis, Am J Med Sci, vol.268, issue.6, pp.336-381, 1974.

S. Rubin, A. Cremer, R. Boulestreau, C. Rigothier, S. Kuntz et al., Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort, J Hypertens, vol.37, issue.2, pp.316-340, 2019.

H. Esh, E. Agabiti, M. A. France, A. D. Uk, F. M. Germany et al., ESC / ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology ( ESC ) and the European Society of, p.p, 2018.

A. Cremer, F. Amraoui, G. Lip, E. Morales, S. Rubin et al., From malignant hypertension to hypertension-MOD: A modern definition for an old but still dangerous emergency, Journal of Human Hypertension, vol.30, pp.463-469, 2016.

J. H. Laragh, L. Baer, H. R. Brunner, F. R. Buhler, and J. E. Vaughan, Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease, Am J Med, vol.52, issue.5, pp.633-52, 1972.

O. B. Paulson, S. Strandgaard, and L. Edvinsson, Cerebrovascular and brain metabolism reviews, Cerebral autoregulation, vol.2, pp.161-92, 1990.

R. V. Immink, B. Van-den-born, G. A. Van-montfrans, R. P. Koopmans, J. M. Karemaker et al., Impaired cerebral autoregulation in patients with malignant hypertension. Circulation, vol.110, pp.2241-2246, 2004.

R. Boulestreau, A. Cremer, A. Lorthioir, S. Rubin, P. L. Tharaux et al., Malignant hypertension: A bright future, Presse Medicale

B. Van-den-born, R. P. Koopmans, J. O. Groeneveld, and G. A. Van-montfrans, Ethnic disparities in the incidence, presentation and complications of malignant hypertension, J Hypertens, vol.24, issue.11, pp.2299-304, 2006.

D. A. Lane, G. Lip, and D. G. Beevers, Improving survival of malignant hypertension patients over 40 years, Am J Hypertens, vol.22, issue.11, pp.1199-204, 2009.

S. Rubin, A. Cremer, R. Boulestreau, C. Rigothier, S. Kuntz et al., Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort, J Hypertens, vol.37, issue.2, pp.316-340, 2019.

G. Lip and M. Beevers, Gareth Beevers D. Complications and survival of 315 patients with malignant-phase hypertension, J Hypertens, vol.13, issue.8, pp.915-939, 1995.

B. Van-den-born, U. Honnebier, and R. P. Koopmans, Van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension

, Hypertension, vol.45, issue.2, pp.246-51, 2005.

B. Van-den-born, N. V. Van-der-hoeven, E. Groot, P. J. Lenting, and J. Meijers,

M. Levi, Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension, Hypertension, 2008.

S. Timmermans, A. , M. A. Vanderlocht, J. Damoiseaux, J. Reutelingsperger et al., Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities

, Kidney Int, vol.91, issue.6, pp.1420-1425, 2017.

S. S. Hayreh, G. E. Servais, and P. S. Virdi, Fundus Lesions in Malignant Hypertension: IV. Focal Intraretinal Periarteriolar Transudates, Ophthalmology, vol.93, issue.1, pp.60-73, 1986.

P. Gosse, J. E. Coulon, P. Cremer, A. Papaioannou, G. Yeim et al., ECG detection of left ventricular hypertrophy: The simpler, the better?, J Hypertens, 2012.

D. D. Schocken, Electrocardiographic left ventricular strain pattern: Everything old is new again, Journal of Electrocardiology, vol.47, pp.595-603, 2014.

F. U. Huwez, S. D. Pringle, and P. W. Macfarlane, Variable patterns of ST-T abnormalities in patients with left ventricular hypertrophy and normal coronary arteries, Br Heart J, vol.67, issue.4, pp.304-311, 1992.

P. Gosse, P. Coulon, G. Papaioannou, J. Litalien, and P. Lemetayer, Impact of malignant arterial hypertension on the heart, J Hypertens, vol.29, issue.4, pp.798-802, 2011.

P. Gosse, P. Coulon, G. Papaioannou, J. Litalien, and P. Lemetayer, Impact of malignant arterial hypertension on the heart, J Hypertens, vol.29, issue.4, pp.798-802, 2011.

S. Kuntz, . Multimodale, . Retentissement, . De-l'hypertension-artérielle, and . Maligne, , 2017.

W. G. Hundley, D. A. Bluemke, J. P. Finn, S. D. Flamm, M. A. Fogel et al.,

. Accf/acr/aha/nasci/scmr, expert consensus document on cardiovascular magnetic resonance: A report of the american college of cardiology foundation task force on expert consensus documents, Circulation. 2010, pp.2462-508, 2010.

A. M. Maceira and R. H. Mohiaddin, Cardiovascular magnetic resonance in systemic hypertension, J Cardiovasc Magn Reson, vol.14, issue.1, pp.1-17, 2012.

S. J. Gandy, S. A. Waugh, R. S. Nicholas, H. J. Simpson, W. Milne et al., Comparison of the reproducibility of quantitative cardiac left ventricular assessments in healthy volunteers using different MRI scanners: A multicenter simulation, J Magn Reson Imaging, 2008.

F. Grothues, G. C. Smith, J. Moon, N. G. Bellenger, P. Collins et al., Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy, Am J Cardiol, vol.90, issue.1, pp.29-34, 2002.

T. A. Treibel, F. Zemrak, D. M. Sado, S. M. Banypersad, S. K. White et al., Extracellular volume quantification in isolated hypertension -changes at the detectable limits?, J Cardiovasc Magn Reson, vol.17, issue.1, pp.1-11, 2015.

K. Gusev, A. A. Domenighetti, L. Delbridge, T. Pedrazzini, E. Niggli et al.,

, Angiotensin II-mediated adaptive and maladaptive remodeling of cardiomyocyte excitation-contraction coupling, Circ Res, 2009.

E. Dall'armellina, N. Karia, A. C. Lindsay, T. D. Karamitsos, V. Ferreira et al., Dynamic changes of edema and late gadolinium enhancement after acute myocardial infarction and their relationship to functional recovery and salvage index, Circ Cardiovasc Imaging, 2011.

S. Matsuda, S. Umemoto, K. Yoshimura, S. Itoh, T. Murata et al., Journal of Atherosclerosis and Thrombosis Accepted for publication, 2015.

, Angiotensin Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4 Advance Publication Journal of Atherosclerosis and Thrombosis Accep, J Atheroscler Thromb, 2015.

S. P. Lee, W. Lee, J. M. Lee, E. A. Park, H. K. Kim et al., Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis, Radiology, vol.274, issue.2, pp.359-69, 2015.

H. Vogelsberg, H. Mahrholdt, C. C. Deluigi, A. Yilmaz, E. M. Kispert et al., Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis. Noninvasive Imaging Compared to Endomyocardial Biopsy, J Am Coll Cardiol, vol.51, issue.10, pp.1022-1052, 2008.

T. C. Wong, K. M. Piehler, I. A. Kang, A. Kadakkal, P. Kellman et al., Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission, Eur Heart J, 2014.

A. S. Flett, D. M. Sado, G. Quarta, M. Mirabel, D. Pellerin et al., Diffuse myocardial fibrosis in severe aortic stenosis: An equilibrium contrast cardiovascular magnetic resonance study, Eur Heart J Cardiovasc Imaging, 2012.

N. M. Keith, H. P. Wagener, and J. W. Kernohan, The syndrome of malignant hypertension, Arch Intern Med, vol.41, issue.2, pp.141-88, 1928.

N. M. Keith, H. P. Wagener, and N. W. Barker, Some different types of essential hypertension: their course and prognosis, Am J Med Sci, vol.268, issue.6, pp.336-381, 1974.

B. Van-den-born, R. P. Koopmans, J. O. Groeneveld, and G. A. Van-montfrans, Ethnic disparities in the incidence, presentation and complications of malignant hypertension, J Hypertens, vol.24, issue.11, pp.2299-304, 2006.

D. A. Lane, G. Lip, and D. G. Beevers, Improving survival of malignant hypertension patients over 40 years, Am J Hypertens, vol.22, issue.11, pp.1199-204, 2009.

S. Rubin, A. Cremer, R. Boulestreau, C. Rigothier, S. Kuntz et al., Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort, J Hypertens, vol.37, issue.2, pp.316-340, 2019.

A. Cremer, F. Amraoui, G. Lip, E. Morales, S. Rubin et al., From malignant hypertension to hypertension-MOD: A modern definition for an old but still dangerous emergency, Journal of Human Hypertension, vol.30, pp.463-469, 2016.

P. Gosse, P. Coulon, G. Papaioannou, J. Litalien, and P. Lemetayer, Impact of malignant arterial hypertension on the heart, J Hypertens, 2011.

P. Lintingre, H. Nivet, S. Clément-guinaudeau, C. Camaioni, S. Sridi et al., High-Resolution Late Gadolinium Enhancement Magnetic Resonance for the Diagnosis of Myocardial Infarction With Nonobstructed Coronary Arteries, JACC Cardiovasc Imaging, 2020.

N. Kawel-boehm, A. Maceira, E. R. Valsangiacomo-buechel, J. Vogel-claussen, E. B. Turkbey et al., Normal values for cardiovascular magnetic resonance in adults and children, Journal of Cardiovascular Magnetic Resonance. BioMed Central Ltd, vol.17, 2015.

E. Dall'armellina, N. Karia, A. C. Lindsay, T. D. Karamitsos, V. Ferreira et al., Dynamic changes of edema and late gadolinium enhancement after acute myocardial infarction and their relationship to functional recovery and salvage index, Circ Cardiovasc Imaging, 2011.

N. Kawel-boehm, A. Maceira, E. R. Valsangiacomo-buechel, J. Vogel-claussen, E. B. Turkbey et al., Normal values for cardiovascular magnetic resonance in adults and children, J Cardiovasc Magn Reson, vol.17, issue.1, pp.1-33, 2015.

R. Hinojar, N. Varma, N. Child, B. Goodman, A. Jabbour et al., T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings from the International T1 Multicenter Cardiovascular Magnetic Resonance Study, Circ Cardiovasc Imaging, vol.8, issue.12, 2015.

P. Kong, P. Christia, and N. G. Frangogiannis, The pathogenesis of cardiac fibrosis, vol.71, pp.549-74, 2014.

L. Guo, A. Yin, Q. Zhang, T. Zhong, O. St et al., Angiotensin-(1-7) attenuates angiotensin II-induced cardiac hypertrophy via a Sirt3-dependent mechanism, Am J Physiol -Hear Circ Physiol, vol.312, issue.5, pp.980-91, 2017.

K. Gusev, A. A. Domenighetti, L. Delbridge, T. Pedrazzini, E. Niggli et al., Angiotensin II-mediated adaptive and maladaptive remodeling of cardiomyocyte excitation-contraction coupling, Circ Res, 2009.

J. I. Sadoshima and S. Izumo, Molecular characterization of angiotensin IIinduced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts critical role of the AT1 receptor subtype, Circ Res, vol.73, issue.3, pp.413-436, 1993.

S. Kuntz, Analyse mulimodale du retentissement myocardique de l'hypertension artérielle maligne : comment expliquer l'élévation de la troponine, 2017.

P. Haaf, P. Garg, D. R. Messroghli, D. A. Broadbent, J. P. Greenwood et al., Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: A comprehensive review, J Cardiovasc Magn Reson, vol.18, issue.1, pp.1-12, 2016.

D. R. Messroghli, J. C. Moon, V. M. Ferreira, L. Grosse-wortmann, T. He et al., Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imagin, J Cardiovasc Magn Reson, vol.19, issue.1, pp.1-24, 2017.

F. Grothues, G. C. Smith, J. Moon, N. G. Bellenger, P. Collins et al., Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy, Am J Cardiol, vol.90, issue.1, pp.29-34, 2002.

S. J. Gandy, S. A. Waugh, R. S. Nicholas, H. J. Simpson, W. Milne et al., Comparison of the reproducibility of quantitative cardiac left ventricular assessments in healthy volunteers using different MRI scanners: A multicenter simulation, J Magn Reson Imaging, 2008.

T. C. Wong, K. M. Piehler, I. A. Kang, A. Kadakkal, P. Kellman et al., Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission, Eur Heart J, 2014.

R. E. Schmieder, F. Wagner, M. Mayr, C. Delles, C. Ott et al., The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: The results of a randomized, double-blind, active-controlled study, Eur Heart J, vol.38, issue.44, pp.3308-3325, 2017.

B. Dahlof, R. Devereux, U. De-faire, F. Fyhrquist, T. Hedner et al., The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study rationale, design, and methods, American Journal of Hypertension, vol.10, pp.705-718, 1997.

P. Kimmelstiel and C. Wilson, Benign and Malignant Hypertension and Nephrosclerosis: A Clinical and Pathological Study, Am J Pathol, 1936.

S. S. Hayreh, G. E. Servais, and P. S. Virdi, Fundus Lesions in Malignant Hypertension: IV. Focal Intraretinal Periarteriolar Transudates, Ophthalmology, vol.93, issue.1, pp.60-73, 1986.

S. Rubin, A. Cremer, R. Boulestreau, C. Rigothier, S. Kuntz et al., Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort, J Hypertens, vol.37, issue.2, pp.316-340, 2019.

C. A. Miller, J. H. Naish, P. Bishop, G. Coutts, D. Clark et al., Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume, Circ Cardiovasc Imaging, vol.6, issue.3, pp.373-83, 2013.

S. P. Lee, W. Lee, J. M. Lee, E. A. Park, H. K. Kim et al., Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis, Radiology, vol.274, issue.2, pp.359-69, 2015.

V. Knobelsdorff-brenkenhoff, F. Schüler, J. Dogangüzel, S. Dieringer, M. A. Rudolph et al., Detection and Monitoring of Acute Myocarditis Applying Quantitative Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging, vol.10, 2017.

R. Boulestreau, A. Cremer, A. Lorthioir, S. Rubin, P. L. Tharaux et al., Malignant hypertension: A bright future, Presse Medicale

. Serment-d'hippocrate, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admis(e) dans l'intimité des personnes, je tairai les secrets qui me seront confiés

, Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs. Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Résumé Contexte : L'atteinte cardiaque est aujourd'hui reconnue dans le cadre de la définition de l'HTA maligne. Elle peut se manifester par u ne élévation de troponine, une dysfonction systolique ou encore une hypertrophie ventriculaire gauche disproportionnée, Sa patho génèse reste néanmoins incertaine. L'IRM cardiaque semble un outil idéal pour progresser dans la compréhension de sa physiopathologie

, Les IRM étaient considérées en phase aiguë si le délai de réalisation post diagnostic était inférieur ou égal à 40 jours. Nous avons recueilli les volumes télédiastolique, télésystolique, la FEVG, la masse ventriculaire gauche, la cinétique segmentaire à partir de séquences SSFP, et la présence ou non de rehaussement tardif pathologique 10 minutes après injection de chélate de gadoli nium par une séquence PSIR (± HR), Méthode : Nous avons inclus rétrospectivement les patients de la cohorte bordelaise d'HTA maligne ayant bénéficié d'une IRM cardiaque entre janvier 2009 et janvier 2020

, Le délai moyen de réalisation de l'IRM cardiaque était de 20,9 jours (±17,8). 33 patients ont bénéficié d'une IRM en phase aiguë, réalisée avec un délai moyen de 14, Résultats : Nous avons inclus 39 patients sur les 202 présents dans la cohorte bordelaise

, Seuls deux patients présentaient du rehaussement sous endocardique sans contexte évocateur de syndrome coronarien aigu. Une IRM de suivi a été réalisée chez 18 de ces patients retrouvant une diminution significative de la MVG indexée (92,8 ± 20,1gr/m² (p < 0,05)) et une majoration, Les données de l'IRM dans ce sous-groupe retrouvaient une MVG indexée moyenne de 127,1 gr/m² (± 41,8)

, Conclusion : Ces données suggèrent que l'HVG disproportionnée parfois observée à la phase aiguë d'HTA maligne semble secondaire à un mécanisme mixte. Ce dernier associerait une hyperplasie myocytaire et une atteinte fibrotique excessive, probablement sous l'effet de l'hyperactivation du SRAA. L'absence de séquelle ischémique sur les séquences de rehaussement tardif chez la majorité des patients suggère une cause microvasculaire diffuse expliquant l'ischémie myocardique

, Mots clés : hypertension artérielle maligne, imagerie par résonance magnétique cardiaque, hypertrophie ventriculaire gauche Abstract Context: Cardiac damage is now recognized as part of the definition of malignant hypertension. It can manifest itself as troponin elevation, systolic dysfunction or disproportionate left ventricular hypertrophy. However, its pathogenesis remains uncertain. Cardiac MRI seems to be an

, MRIs were considered acute if the post-diagnosis delay was less than or equal to 40 days. We collected telediastolic, telestolic, LVEF, left ventricular mass, segmental kinetics from SSFP sequences, and the presence or absence of pathological late enhancement 10 minutes after injection of gadolinium chelate by a PSIR sequence (± HR). The most recent cardiac MRIs included T2-weighted and T1 mapping sequences, 2009.

, The mean time to complete cardiac MRI was 20.9 days (±17.8). 33 patients received an acute MRI, performed with a mean time of 14.8 days (±10.3). MRI data in this subgroup showed a mean indexed LVM of 127.1 g/m² (±41.8). There were no significant anomalies on the T2-weighted sequences

, Late enhancement abnormalities were found in 34.4% of patients, mostly of mesomyocardial location. Only two patients had subendocardial elevation without a context suggestive of acute coronary syndrome. Follow-up MRI was performed in 18 of these patients with a significant decrease in indexed LVM (92.8 ± 20.1gr/m² (p < 0.05)) and a significant

, Conclusion: These data suggest that the disproportionate LVH sometimes observed in the acute phase of malignant hypertension appears to be secondary to a mixed mechanism. The latter would associate myocyte hyperplasia and excessive fibrotic damage

, Key words : malignant hypertension, cardiac magnetic resonance imaging